Report
Pharma Mar : Q1 2022 results somewhat below estimates. Solid cash position for M&A
>Q1 2022 numbers showed higher sales and royalties from Zepzelca - Total revenues maintained some growth at +2% y-o-y in Q1 2022 (vs +6% in Q4 2021), in line with our estimates. Biopharma sales increased +1% y-o-y in Q1 2022 (compared to +11% in Q4) reflecting lower Yondelis pricing (-7% y-o-y vs +13% in Q4), an impact which was offset by Zepzelca sales in Europe under the temporary use authorisation programme (ATU). Sales at the diagnostic division recovered traction...
Underlying
Pharma Mar SA
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Isabel Carballo
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.